US FDA approves Novartis' gene therapy for rare muscle disorder

The US FDA has approved Novartis' new gene therapy, Itvisma, which is for patients aged two and above with spinal muscular atrophy. Itvisma offers a new option for a broader patient group. The therapy aims to replace a faulty gene crucial for muscle function.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WXvlp1M
via IFTTT